Gilead Sciences, Inc.

Gilead Pharmasset LLC

Terns, Inc.

Terns Pharmaceuticals, Inc.

Biomea Fusion, Inc.

Korea Research Institute of Chemical Technology

Thorsten A Kirschberg

William John Watkins

Aesop Cho

Hyung-Jung Pyun

Richard L Mackman

John O Link

James G Taylor

Choung U Kim

Randall Halcomb

Maria Fardis

Jeromy J Cottell

Michael L Mitchell

Elizabeth M Bacon

James Ming Chen

Lee Shun Chong

Xiaowu Chen

Scott D Schroeder

Neil H Squires

Manoj C Desai

Scott E Lazerwith

Carina E Cannizzaro

Jennifer R Zhang

Adrian S Ray

Sundaramoorthi Swaminathan

Hongyan Guo

Lianhong Xu

Darryl Kato

Jay P Parrish

Christopher P Lee

Gary Bruce Phillips

F Anthony Romero

Winston C Tse

Eda Y Canales

David A Oare

Hongtao Liu

Nathan E Wright

Musong Kim

Jianyu Sun

Evan S Krygowski

Gayatri Balan

Alan X Huang

James D Trenkle

Joseph H Saugier

Yingzi Xu

Michael Graupe

Qi Liu

Randall W Vivian

Constantine G Boojamra

David Y Markevitch

Chien-Hung Chou

Vidya K Prasad

Ralph F Hirschmann

Sheila M Zipfel

William A Lee

Haolun Jin

Christopher T Clark

Kirk L Stevens

Peter H Nelson

Rosemarie Sherlock

Kuei-Ying Lin

Rick Andrew Lee

Jinfa Du

Tetsuya Kobayashi

Jonathan William Medley

Joshua A Kaplan

Philip Anthony Morganelli

Steven H Krawczyk

Sophia L Shevick

Lijun Zhang

Roland D Saito

James T Palmer

Craig S Gibbs

Rosemarie O'Shea

Chandrasekar Venkataramani

Shuang Shuang Li

Barton W Phillips

Nan-Horng Lin

Chienhung Chou

Thomas Butler

Xiaodong Wang

Samuel E Metobo

Michael R Mish

Ming Gao

Thu Phan

Ravindra B Upasani

Yongli Su

Ill Young Lee

Jong Chan Son

Angelina Sau Man Wong

Heow Meng Tan

Hongyan He

Sundaramoorthi Swaninathan

Hyung-Jun Pyun

David Sperandio

Solomon B Ungashe

Amna Trinity-Turjuman Adam

Neil Howard Squires

Yanjing Zhou

Yuyao Gu

Provided herein are compounds, preferably (R)-N-(4-(chlorodifluoromethoxy) phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide having the Formula I or a pharmaceutically acceptable salt or tautomer thereof, that inhibits tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Thyroid hormone receptor beta agonist compounds

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),

Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]

This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Substituted pyrrolizine compounds and uses thereof

Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Pyrazine compounds as inhibitors of FLT3

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.

Tricyclic ASK1 inhibitors

Provided herein are compounds of formula (I) or formula (Ia) that inhibit tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. 

Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias

Growing community of inventors

Redwood City, CA, United States of America

Thorsten A Kirschberg